Slide 1: VISIONARY-MS Study Long-Term Open Label Extension
Phase 2 VISIONARY-MS STUDY Long-Term Open Label Extension In Stable RMS Participants with Chronic Optic Neuropathy Michael Barnett, MBBS PhD FRACP FRCP. On behalf of the VISIONARY-MS Investigators
Slide 2: Disclosures
Disclosures csonanins ‘opentabel Extension The University of Sydney received industry standard financial renumeration as a clinical trial site 1am a consulting research director for Sydney Neuroimaging Analysis Centre (SNAC), which was contracted to analyse blinded MRI and VEP data | ama consulting
Slide 3: Treatment and Participant Disposition in the Long-Term Extension
@VISIONARY-MS Treatment and Participant Disposition in the Long-Term Extension Long-term CNM-Au8 30mg Oral Suspension Clean Surtaced, Highly FacetedNanocrystals Cellular Energetic Nanocatalyst: Mitochondrial Support Original CNM-Au8 to CNM-Au8 LTE n=gt (8 & Increased Energetic Capacity in Neurons an
Slide 4: Clinical Results | Long-Term LCLA Improvement
eVISIONARY.-MS Clinical Results | Long-Term LCLA Improvement Long-term Low Contrast Letter Acuity (Original Double-Blind Primary Endpoint) ak Original CNM-Aus. Ex-Placebo to CNM-Au8 feu ps al | = Oe ii » sue L.. ie aael He Hy Ho] ity! ES < Cpa Peas ra i + omnavn LTE Ls mean cterene ws randomization
Slide 5: Multi-Focal VEP | Long-Term Amplitude Improvement
eVISIONARY.-MS Multi-Focal VEP | Long-Term Amplitude Improvement rave etn Visual Pathway Signal Strength co = Original CNM-Au8 Ex-Placebo to CNM-Au8 Er Agta Lng ec ng IVE Amptue|xPaceb Longtcial Percet 6) change nic bocplu paces neues peach wire Pes fete seo Albena ronda Pesan tnsectonttone otecer e
Slide 6: Multi-Focal VEP | Long-Term Latency Improvement
eVISIONARY.-MS Multi-Focal VEP | Long-Term Latency Improvement Label exension Visual Pathway Conduction Velocity ick = Original CNM-Au8 Ex-Placebo to CNM-Au8 ‘Ve erage Latency Lng Percat ()Cange sn EP Average Latny |Longtutnal Percent) Change Tire racpes scat Ete Pa MUTE atc (epics) Al Evatt Percont
Slide 7: OCT | Long-Term Ganglion Cell Layer Preservation
eVISIONARY.-MS OCT | Long-Term Ganglion Cell Layer Preservation tenga GCL Volume Change in the Most Affected Eyes at Baseline Kotha 5 Original CNM-Au8: Ex-Placebo to CNM-Au8 Ganglion Cell Layer Volume (mm?) in Most Affected Eyes (At Baseline, n=49 of 146) Ganglion Cell Layer Volume (mm?) in Most Aff
Slide 8: Clinical Results | Long-Term SDMT Improvement
Clinical Results | Long-Term SDMT Improvement OUISIONARY a Working Memory and Cognition (Original Exploratory Endpoint) Aol 9s ae Original CNM-Au8 Ex-Placebo to CNM-Au8 _ | eS tee cen cane see caer oe ee es ee ees it : / im Aw” He i oe i i | ASSt \ a) LN BO Sart u e [ He SaaS —* Soe ee aeons ee = on
Slide 9: MRI DTI | Evidence for Remyelination and Axonal Integrity
MRI DTI | Evidence for Remyelination and Axonal Integrity has abel Diffusion Tensor Imaging | T2 Lesion Axial Diffusivity and Myelination Metrics cen T2 Lesion MWF 2 Lesion MTR T2 Lesion Axial Diffusivity. In the Cerebrum In the Cerebrum In the Cerebrum eu ogame donn ot ata Pat "tomscnaren en nese c
Slide 10: CNM-Au8 Safety Summary
CNM-Au8 Safety Seis: ‘opentabel Extension CNM-Au8 treatment was safe and well-tolerated during the LTE Treatment emergent adverse events (TEAES) were transient and predominantly mild-to-moderate 6 SAEs were reported over 82.9 years of cumulative participant follow-up including: (2) nephrolithiasis,